SYRESpyre Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+16% of shares).
Choppy, but holding above its 200-day average. Price is +32% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 9, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SYRE is trading
Spyre Therapeutics, Inc. is +476% over the past year while the S&P 500 is +18%: 458 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +32%
vs 200-day average · a clear uptrend
- RSI (14)
- 41
RSI (14) · neutral
- Below its 52-week high
- 21%
Below its 52-week high
Details›
- Last close2026-10-09
- $85.70
- 1 monthS&P 500 +2.7%
- −3.4%
- 1 yearS&P 500 +18%
- +476%
- 5 yearsS&P 500 +88%
- −51%
- vs 50-day average$94.20
- −9.0%
- 52-week high
- $108.94
- 52-week low
- $15.29
- Annualised volatility
- 69%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09
- −$401M
| Year | Return |
|---|---|
| 2026 (year to date) | +162% |
| 2025 | +41% |
| 2024 | +8.2% |
| 2023 | +91% |
| 2022 | −91% |
| 2021 | −40% |
| 2020 | +3.0% |
| 2019 | +2.0% |
| 2018 | +38% |
| 2017 | +24% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +3.5% |
| Feb | 10 | 5 of 10 | +2.9% |
| Mar | 10 | 5 of 10 | +2.2% |
| Apr | 10 | 2 of 10 | −0.99% |
| May | 10 | 5 of 10 | −4.6% |
| Jun | 10 | 5 of 10 | +18% |
| Jul | 11 | 5 of 11 | +0.93% |
| Aug | 11 | 8 of 11 | +9.0% |
| Sep | 11 | 6 of 11 | +1.5% |
| Oct | 11 | 4 of 11 | +9.6% |
| Nov | 10 | 4 of 10 | +0.50% |
| Dec | 10 | 4 of 10 | −1.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.